re: + + aod9604 clinical trial recruitment update
April 7
AOD9604 Clinical Trial Recruitment Update
We are pleased to advise that as of last Friday, 225 patients have now been enrolled in the Company’s 300-patient Phase 2b clinical trial on obesity drug AOD9604, reflecting a substantial increase in the recruitment rate.
A further update will be provided on completion of enrolment.
About Metabolic Metabolic Pharmaceuticals Limited is a biotechnology company based in Melbourne, Australia, and listed on the Australian Stock Exchange (ASX: MBP).
The Company’s mission is to develop a pipeline of new pharmaceuticals for world markets, and currently has active programs aimed at treating obesity (AOD9604 in Phase 2b human trials), pain (ACV1 in preclinical toxicology), type 2 diabetes, and osteoporosis.
Further details are available at www.metabolic.com.au. Contact Information: Ph +61 3 9860 5700 Chris Belyea CEO [email protected] David Kenley VP Corporate Development [email protected]
MBP Price at posting:
0.0¢ Sentiment: None Disclosure: Held